The company said, “MaxCyte (MXCT) increases 2024 revenue guidance for core business revenue and affirms SPL Program-related revenue guidance. MaxCyte now expects full year 2024 core business revenue of 6% to 8% growth compared to 2023. SPL Program-related revenue is expected to be approximately $6 million. The outlook for the full year does not include SPL Program-related revenue from Vertex/CRISPR’s CASGEVY. MaxCyte continues to expect to end 2024 with approximately $185 million in cash, cash equivalents and investments.”
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MXCT:
- MaxCyte Streamlines Workforce and Boosts Revenue Outlook
- MaxCyte Expands Stock Capital Amid Cell Therapy Growth
- MaxCyte’s Voting Rights Shift with BlackRock Acquisition
- MaxCyte Sees Shift in BlackRock’s Shareholding
- MaxCyte Weighs Delisting from AIM to Prioritize Nasdaq: Potential Benefits and Risks Ahead